Name: Paraganglioma Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: PH3389
Price: 4350 USD
Availability: InStock

Paraganglioma Treatment Market Analysis, Size and Report 2023-2030

Paraganglioma Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Global Paraganglioma Treatment Market is segmented By Site of origin (Carotid paraganglioma, Vagal paraganglioma, Cervical paraganglioma, Others), By Treatment Type (Peptide Receptor Radionuclide Therapy, Surgery, Chemotherapy, Radiation therapy, Others), By End-users (Hospitals, Specialty Clinics, Cancer research institutes, Others), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030</h2>

&nbsp;

<h2>Market Overview</h2>

<blockquote>
[180 Pages&nbsp;Report]&nbsp;The Global Paraganglioma Treatment Market is expected to grow at a&nbsp;CAGR of 6.42%&nbsp;during the forecasting period (2023-2030).
</blockquote>

Paraganglioma Treatment Market -&nbsp;Strategic Insights

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			&nbsp;6.42%
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Site of origin,&nbsp;By Treatment Type,&nbsp;By End-users and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

To Get a Free Sample <a href="https://www.datamintelligence.com/download-sample/paraganglioma-treatment-market">Click here</a>

Paraganglioma is a neuroendocrine tumor that forms near certain blood vessels and nerves outside of the adrenal glands. The adrenal glands are essential for making hormones that control many functions in the body and are located on top of the kidneys, and the nerve cells involved in paraganglioma are part of the peripheral nervous system. These tumors can also be called Extra-adrenal pheochromocytomas. Approximately 35-50% of paragangliomas may spread to other parts of the body. It is most often found in people aged 30 to 50 years old. Some signs and symptoms of paraganglioma occur when too much adrenaline or noradrenaline is released into the blood are High blood pressure, Headache, Heavy sweating for no known reason, A strong, fast, or irregular heartbeat, being shaky, Being extremely pale. The treatment includes Surgery, Radiation therapy, Chemotherapy, Ablation therapy, Embolization therapy, Targeted therapy. The market is expected to drive in the future due to the increasing prevalence rate of rare cancers.

<h2>Market Dynamics</h2>

The global Paraganglioma Treatment market growth is driven by the growing prevalence of paraganglioma cases, rapidly changing lifestyle, growing number of clinical trials of drugs and continuous advancements in novel treatments, Rising healthcare expenditure are the major factors driving the market.

Increase Prevalence of Paraganglioma Cancers is expected to drive the market during the forecast period.

As per the National Library of Medicine, it is estimated that the prevalence of pheochromocytoma is 1 in 500,000 people, and the prevalence of other paragangliomas is 1 in 1 million people. These statistics include syndromic and non-syndromic paraganglioma and pheochromocytoma.

Increased Drug approvals, is expected to drive the market during the forecast period.

Enterome is a clinical-stage company conducting a Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination with Immune Check Point Blockade (nivolumab) Treatment of Patients with Locally Advanced or Metastatic Malignant Pheochromocytoma/Paraganglioma.

Molecular Insight Pharmaceuticals, Inc got approval for marketing by conducting a study on expanded access of AZEDRA (Ultratrace Iobenguane I 131) and to evaluate the safety and tolerability of AZEDRA in subjects with iobenguane-avid malignant and recurrent pheochromocytoma/paraganglioma (PPGL).

Lack of awareness about the disease is likely to hinder market growth.

Government and private organisations should initiate and implement awareness programs about paraganglioma cancer as it is a rare type of cancer it may lead to the advanced stage under no proper guidance and awareness. This may hamper the market growth majorly.

<h2>COVID-19 Impact Analysis</h2>

The COVID-19 pandemic has negatively impacted healthcare systems globally and on the vulvar Cancer market. According to the Centres for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the Ongoing clinical trials too. However, the situation is expected to improve gradually.

<h2>Segment Analysis</h2>

Based on Treatment Type, the global Paraganglioma Treatment market is segmented into Surgery, Peptide Receptor Radionuclide Therapy (PRRT) Chemotherapy, Radiation therapy.

The peptide Receptor Radionuclide Therapy (PRRT) segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)&nbsp;

Radionuclide therapy implicates the usage of radiolabeled peptides with high affinity to the involved receptor. In addition to surgery and chemotherapy, 131I-MIBG (Azedra) treatment has been effectively used to manage malignant and metastatic Paraganglioma cancers. In August 2018, Progenics Pharmaceuticals, Inc received approval from the FDA for Azedra (iobenguane I131), a radioactive therapeutic agent for locally advanced or metastatic treatment pheochromocytoma or paraganglioma in adult and pediatric patients 12 years and older.&nbsp; It has also received Breakthrough Therapy designation, an Orphan Drug designation, Fast Track designations and Priority Review from the FDA to treat iobenguane-avid metastatic paraganglioma and pheochromocytoma. The approval of Azedra represents significant advances in non-surgical treatment for ultra-rare cancer paraganglioma.

Additionally, Advanced Accelerator Applications has recently been used in metastatic Paraganglioma cancers, 177Lu-DOTATATE (Lutathera&reg;) therapy.

Based on Site of Origin, the global Paraganglioma Treatment market is segmented into Carotid paragangliomas, Vagal paragangliomas, Cervical paragangliomas.

Carotid paragangliomas&nbsp;appear with an expanding and pulsing mass. When this paraganglioma appears as a superficial, isolated lesion, you may experience relatively few symptoms. These tumors usually appear in the neck but can extend into the space between the head and the neck.&nbsp;

Cervical paragangliomas&nbsp;are slow-growing tumors that can cause palsy and spread into the skull base. It can be challenging to distinguish between tumors that affect the vagus and those that involve the carotid artery.

Vagal paragangliomas&nbsp;can cause paralysis to the lower cranial nerves (including the 10th cranial nerve, which can cause paralysis of the diaphragm), 12th cranial nerve paralysis (with paralysis of the tongue), problems in swallowing, and problems with raising your shoulder.

&nbsp;

Based on End-User, the global Paraganglioma Treatment market is segmented into Hospitals, Cancer Research centres, Speciality Clinics, others.

Due to the growing patient population, the hospital&#39;s segment held the largest market share. This is mainly owing to the increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment. Also, the medications can only be administrated intravenously and surgery is done under the supervision of medical practioners at these locations.

<h2>Geographical Analysis</h2>

North America served the largest share of the market due to the presence of major market players developing oncology products. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel radionuclide therapy and Radiation therapy methods, the total availability of advanced diagnostic tools. For instance, Clinical Study of the Use of Yttrium-90 (90Y) and/or Lutecium-177 (177Lu) DOTATATE (DOTA-0-Tyr3-Octreotate) in the Treatment of Disseminated and/or Symptomatic Tumors With Somatostatin Receptor Overexpression is under phase 2 clinical trials by the University of Warmy and Mazury.

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to the increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Ono Pharmaceuticals, Yervoy injection (Ipilimumab) Anti-CTLA-4 antibody is under Phase 3 clinical trials to treat patients with Head and Neck cancers.

<h2>Competitive Landscape&nbsp;</h2>

The global Paraganglioma Treatment market is quite competitive with some key competitors like Progenics Pharmaceuticals, Inc, AstraZeneca, Advanced Accelerator Applications, Jubilant Life Sciences Ltd, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Cipla Inc, Amneal Pharmaceuticals LLC, Apotex Inc, Ono Pharmaceuticals. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors.&nbsp;

For instance, according to clinicaltrials.gov; A Phase II Study to Evaluate the Effects of Cabozantinib in Patients with Unresectable Metastatic Pheochromocytomas and Paragangliomas by M.D. Anderson Cancer Center in collaboration with National Cancer Institute (NCI).

Advanced Accelerator Applications

Company Overview:&nbsp;Advanced Accelerator Applications (AAA) was founded in 2002 by Stefano Buono, who was inspired to pursue medical applications for certain research conducted during his tenure at the European Organization for Nuclear Research, or CERN, with Nobel laureate Carlo Rubbia. Built first radiopharmaceutical laboratory in the Technoparc of Saint-Genis-Pouilly (France). In 2004, Achieved first Marketing Authorization to commercialize GLUSCAN&reg; in Switzerland. In 2009, Completed the acquisition of Gipharma, an Italian pharmaceutical contract manufacturer for injectable and freeze-dried products. In 2010, Acquired BioSynthema Inc., a U.S. molecular nuclear medicine discovery company based in St. Louis, Missouri, to obtain the rights to develop and commercialize LUTATHERA&reg; (lutetium Lu 177 dotatate). In 2018, <a href="https://www.novartis.com/news/media-releases/advanced-accelerator-applications-receives-fda-approval-lutathera-treatment-gastroenteropancreatic-neuroendocrine-tumors">AAA, acquired by Novartis</a>, got FDA approval of LUTATHERA&reg; (lutetium 177Lu oxodotreotide).

Product Portfolio: The Company&rsquo;s portfolio comprised of include targeted radioligand therapy in oncology and several precision imaging products mainly used in clinical oncology, cardiology, neurology and infectious/inflammatory diseases.

Key developments:

Advanced Accelerator Applications are undergoing Phase I Trial of Peptide Receptor Radiotherapy (PRRT) With 177Lu-DOTA-tyr3-Octreotate (177Lu-DOTATATE) in Children and Adolescents with Neuroendocrine Tumor or Pheochromocytoma/Paraganglioma.

Why Purchase the Report?

<ul>
	<li>Visualize the composition of the Paraganglioma Treatment Market segmentation by Treatment type, Site of origin, End-users, and region highlighting the key commercial assets and players.</li>
	<li>Identify commercial opportunities in Paraganglioma Treatment Market by analyzing trends and co-development deals.&nbsp;</li>
	<li>Excel data sheet with thousands of data points of Paraganglioma Treatment Market - level 4/5 segmentation.</li>
	<li>PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.&nbsp;</li>
	<li>Product mapping in excel for the key product of all major market players</li>
</ul>

The global Paraganglioma Treatment Market report would provide an access to an approx. 61 market data table, 56 figures and 180 pages.&nbsp;

Target Audience

<ul>
	<li>Service Providers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Education &amp; Research Institutes</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
	<li>Manufacturers</li>
</ul>

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics</h3>

<a href="https://www.datamintelligence.com/research-report/plastic-surgery-market">Plastic Surgery Market</a>

<a href="https://www.datamintelligence.com/research-report/chemotherapy-induced-peripheral-neuropathy-treatment-market">Chemotherapy Induced Peripheral Neuropathy Treatment Market</a>

<a href="https://www.datamintelligence.com/research-report/radiation-dose-management-market">Radiation Dose Management Market</a>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Market Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Executive Summary</h3>

	<ol>
		<li>Market Snippet by Site of origin</li>
		<li>Market snippet by Treatment Type</li>
		<li>Market Snippet by End-users</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>Market Dynamics
	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Increasing prevalence of paraganglioma cancers worldwide</li>
				<li>Increased Drug approvals</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Lack of Awareness about the disease</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&#39;s Five Forces Analysis&nbsp;</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Reimbursement Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>COVID-19 Analysis
	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Site of origin</h3>

	<ol>
		<li>Introduction</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site of origin Segment</li>
		<li>Market Attractiveness Index, By Site of origin Segment
		<ol>
			<li>Carotid paraganglioma*</li>
			<li>Introduction</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%)</li>
		</ol>

		<ol>
			<li>Vagal paraganglioma</li>
			<li>Cervical paraganglioma</li>
			<li>Others</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Treatment type</h3>

	<ol>
		<li>Introduction</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type</li>
		<li>Market Attractiveness Index, By Treatment type
		<ol>
			<li>Peptide Receptor Radionuclide therapy*
			<ol>
				<li>Introduction</li>
				<li>Market Size Analysis, and Y-o-Y Growth Analysis (%)</li>
			</ol>
			</li>
			<li>Surgery</li>
			<li>Chemotherapy</li>
			<li>Radiation therapy</li>
			<li>Others</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By End-users</h3>

	<ol>
		<li>Introduction</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users segment</li>
		<li>Market Attractiveness Index, By End-users Segment
		<ol>
			<li>Hospitals*
			<ol>
				<li>Introduction</li>
				<li>Market Size Analysis, and Y-o-Y Growth Analysis (%)</li>
			</ol>
			</li>
			<li>Specialty Clinics</li>
			<li>Cancer research institutes&nbsp;</li>
			<li>Others</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Region</h3>

	<ol>
		<li>Introduction&nbsp;</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region</li>
		<li>Market Attractiveness Index, By Region</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site of origin</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site of origin</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site of origin</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site of origin</li>
			<li>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site of origin</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Company Profiles</h3>

	<ol>
		<li>Advanced Accelerator Applications*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Progenics Pharmaceuticals, Inc,&nbsp;</li>
		<li>AstraZeneca,&nbsp;&nbsp;</li>
		<li>Jubilant Life Sciences Ltd,&nbsp;</li>
		<li>Pfizer Inc,&nbsp;</li>
		<li>Teva Pharmaceutical Industries Ltd,&nbsp;</li>
		<li>Cipla Inc,&nbsp;</li>
		<li>Amneal Pharmaceuticals LLC,&nbsp;</li>
		<li>Apotex Inc,&nbsp;</li>
		<li>Ono Pharmaceuticals.(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Premium Insights</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">DataM Intelligence&nbsp;</h3>

	<ol>
		<li>Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table 1 Global Paraganglioma Treatment Market Value, By Treatment Type, 2021,2025 &amp; 2029 ($ Million)

Table 2 Global Paraganglioma Treatment Market Value, By Site of Origin, 2021,2025 &amp; 2029 ($ Million)

Table 3 Global Paraganglioma Treatment Market Value, By End-Users, 2021,2025 &amp; 2029 ($ Million)

Table 4 Global Paraganglioma Treatment Market Value, By Region, 2021,2025 &amp; 2029 ($ Million)

Table 5 Global Paraganglioma Treatment Market Value, By Treatment Type, 2021,2025 &amp; 2029 ($ Million)

Table 6 Global Paraganglioma Treatment Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 7 Global Paraganglioma Treatment Market Value, By Site of Origin, 2021,2025 &amp; 2029 ($ Million)

Table 8 Global Paraganglioma Treatment Market Value, By Site of Origin, 2018-2029 ($ Million)

Table 9 Global Paraganglioma Treatment Market Value, By End-Users, 2021,2025 &amp; 2029 ($ Million)

Table 10 Global Paraganglioma Treatment Market Value, By End-Users, 2018-2029 ($ Million)

Table 11 Global Paraganglioma Treatment Market Value, By Region, 2021,2025 &amp; 2029 ($ Million)

Table 12 Global Paraganglioma Treatment Market Value, By Region, 2018-2029 ($ Million)

Table 13 North America Paraganglioma Treatment Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 14 North America Paraganglioma Treatment Market Value, By Site of Origin, 2018-2029 ($ Million)

Table 15 North America Paraganglioma Treatment Market Value, By End-Users, 2018-2029 ($ Million)

Table 16 North America Paraganglioma Treatment Market Value, By Country, 2018-2029 ($ Million)

Table 17 South America Paraganglioma Treatment Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 18 South America Paraganglioma Treatment Market Value, By Site of Origin, 2018-2029 ($ Million)

Table 19 South America Paraganglioma Treatment Market Value, By End-Users, 2018-2029 ($ Million)

Table 20 South America Paraganglioma Treatment Market Value, By Country, 2018-2029 ($ Million)

Table 21 Europe Paraganglioma Treatment Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 22 Europe Paraganglioma Treatment Market Value, By Site of Origin, 2018-2029 ($ Million)

Table 23 Europe Paraganglioma Treatment Market Value, By End-Users, 2018-2029 ($ Million)

Table 24 Europe Paraganglioma Treatment Market Value, By Country, 2018-2029 ($ Million)

Table 25 Asia-Pacific Paraganglioma Treatment Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 26 Asia-Pacific Paraganglioma Treatment Market Value, By Site of Origin, 2018-2029 ($ Million)

Table 27 Asia-Pacific Paraganglioma Treatment Market Value, By End-Users, 2018-2029 ($ Million)

Table 28 Asia-Pacific Paraganglioma Treatment Market Value, By Country, 2018-2029 ($ Million)

Table 29 Middle East &amp; Africa Paraganglioma Treatment Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 30 Middle East &amp; Africa Paraganglioma Treatment Market Value, By Site of Origin, 2018-2029 ($ Million)

Table 31 Middle East &amp; Africa Paraganglioma Treatment Market Value, By End-Users, 2018-2029 ($ Million)

Table 32 Advanced Accelerator Applications: Overview

Table 33 Advanced Accelerator Applications: Product Portfolio

Table 34 Advanced Accelerator Applications: Key Developments

Table 35 Progenics Pharmaceuticals, Inc: Overview

Table 36 Progenics Pharmaceuticals, Inc: Product Portfolio

Table 37 Progenics Pharmaceuticals, Inc: Key Developments

Table 38 Jubilant Life Sciences Ltd: Overview

Table 39 Jubilant Life Sciences Ltd: Product Portfolio

Table 40 Jubilant Life Sciences Ltd: Key Developments

Table 41 AstraZeneca: Overview

Table 42 AstraZeneca: Product Portfolio

Table 43 AstraZeneca: Key Developments

Table 44 Pfizer Inc: Overview

Table 45 Pfizer Inc: Product Portfolio

Table 46 Pfizer Inc: Key Developments

Table 47 Teva Pharmaceutical Industries Ltd: Overview

Table 48 Teva Pharmaceutical Industries Ltd: Product Portfolio

Table 49 Teva Pharmaceutical Industries Ltd: Key Developments

Table 50 Cipla Inc: Overview

Table 51 Cipla Inc: Product Portfolio

Table 52 Cipla Inc: Key Developments

Table 53 Amneal Pharmaceuticals LLC: Overview

Table 54 Amneal Pharmaceuticals LLC: Product Portfolio

Table 55 Amneal Pharmaceuticals LLC: Key Developments

Table 56 Ono Pharmaceuticals: Overview

Table 57 Ono Pharmaceuticals: Product Portfolio

Table 58 Ono Pharmaceuticals: Key Developments

Table 59 Apotex Inc: Overview

Table 60 Apotex Inc: Product Portfolio

Table 61 Apotex Inc: Key Developments

List of Figures

Figure 1 Global Paraganglioma Treatment Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 2 Global Paraganglioma Treatment Market Share, By Site of Origin, 2021 &amp; 2029 (%)

Figure 3 Global Paraganglioma Treatment Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 4 Global Paraganglioma Treatment Market Share, By Region, 2021 &amp; 2029 (%)

Figure 5 Global Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 6 Global Paraganglioma Treatment Market Y-o-Y Growth, By Treatment Type, 2021-2029 (%)

Figure 7 Peptide Receptor Radionuclide Therapy: Global Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 8 Chemotherapy: Global Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 9 Radiation Therapy: Global Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 10 Surgery: Global Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 11 Others: Global Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 12 Global Paraganglioma Treatment Market Y-o-Y Growth, By Site of Origin, 2021-2029 (%)

Figure 13 Carotid Paraganglioma: Global Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 14 Vagal Paraganglioma: Global Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 15 Cervical Paraganglioma: Global Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 16 Others: Global Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 17 Global Paraganglioma Treatment Market Y-o-Y Growth, By End-Users, 2021-2029 (%)

Figure 18 Hospitals: Global Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 19 Cancer research institutes: Global Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 20 Specialty Clinics: Global Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 21 Others: Global Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 22 Global Paraganglioma Treatment Market Y-o-Y Growth, By Region, 2021-2029 (%)

Figure 23 North America Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 24 North America Paraganglioma Treatment Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 25 North America Paraganglioma Treatment Market Share, By Site of Origin, 2021 &amp; 2029 (%)

Figure 26 North America Paraganglioma Treatment Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 27 North America Paraganglioma Treatment Market Share, By Country, 2021 &amp; 2029 (%)

Figure 28 South America Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 29 South America Paraganglioma Treatment Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 30 South America Paraganglioma Treatment Market Share, By Site of Origin, 2021 &amp; 2029 (%)

Figure 31 South America Paraganglioma Treatment Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 32 South America Paraganglioma Treatment Market Share, By Country, 2021 &amp; 2029 (%)

Figure 33 Europe Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 34 Europe Paraganglioma Treatment Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 35 Europe Paraganglioma Treatment Market Share, By Site of Origin, 2021 &amp; 2029 (%)

Figure 36 Europe Paraganglioma Treatment Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 37 Europe Paraganglioma Treatment Market Share, By Country, 2021 &amp; 2029 (%)

Figure 38 Asia-Pacific Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 39 Asia-Pacific Paraganglioma Treatment Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 40 Asia-Pacific Paraganglioma Treatment Market Share, By Site of Origin, 2021 &amp; 2029 (%)

Figure 41 Asia-Pacific Paraganglioma Treatment Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 42 Asia-Pacific Paraganglioma Treatment Market Share, By Country, 2021 &amp; 2029 (%)

Figure 43 Middle East &amp; Africa Paraganglioma Treatment Market Value, 2018-2029 ($ Million)

Figure 44 Middle East &amp; Africa Paraganglioma Treatment Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 45 Middle East &amp; Africa Paraganglioma Treatment Market Share, By Site of Origin, 2021 &amp; 2029 (%)

Figure 46 Middle East &amp; Africa Paraganglioma Treatment Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 47 Advanced Accelerator Applications: Financials

Figure 48 Progenics Pharmaceuticals, Inc: Financials

Figure 49 Jubilant Life Sciences Ltd: Financials

Figure 50 AstraZeneca: Financials

Figure 51 Pfizer Inc: Financials

Figure 52 Teva Pharmaceutical Industries Ltd: Financials

Figure 53 Cipla Inc: Financials

Figure 54 Amneal Pharmaceuticals LLC: Financials

Figure 55 Ono Pharmaceuticals: Financials

Figure 56 Apotex Inc: Financials